ProQR Therapeutics (PRQR) Current Leases (2014 - 2026)

ProQR Therapeutics has reported Current Leases for 10 years, with the latest figure at $2.0 million in Q1 2026.

• Quarterly Current Leases rose 30.89% year-over-year to $2.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.0 million (up 30.89% YoY) and the FY2025 annual result came in at $1.8 million, up 7.4% from the prior year.
• Current Leases advanced to $2.0 million in Q1 2026 per PRQR's latest filing, from $1.8 million in the prior quarter.
• Over five years, Current Leases peaked at $2.0 million in Q1 2026 and troughed at $1.4 million in Q3 2022.
• A 5-year average of $1.6 million and a median of $1.6 million in 2024 frame the typical range for Current Leases.
• The sharpest annual moves came in 2022 and 2026: Current Leases slipped 19.36% in 2022, then soared 30.89% in 2026.
• Over 5 years, Current Leases stood at $1.4 million in 2022, then gained by 22.72% to $1.7 million in 2023, then declined by 3.57% to $1.7 million in 2024, then climbed by 7.4% to $1.8 million in 2025, then gained by 11.77% to $2.0 million in 2026.
• According to Business Quant data, Current Leases over the past three periods registered $2.0 million, $1.8 million, and $2.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.